GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology AS (OSTO:SCOL) » Definitions » Debt-to-Asset

Scandion Oncology AS (OSTO:SCOL) Debt-to-Asset : 0.01 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology AS Debt-to-Asset?

Scandion Oncology AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.27 Mil. Scandion Oncology AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Scandion Oncology AS's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was kr58.97 Mil. Scandion Oncology AS's debt to asset for the quarter that ended in Jun. 2024 was 0.00.


Scandion Oncology AS Debt-to-Asset Historical Data

The historical data trend for Scandion Oncology AS's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology AS Debt-to-Asset Chart

Scandion Oncology AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial - - 0.01 0.02 0.01

Scandion Oncology AS Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.01 0.01 0.01

Competitive Comparison of Scandion Oncology AS's Debt-to-Asset

For the Biotechnology subindustry, Scandion Oncology AS's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scandion Oncology AS's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scandion Oncology AS's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Scandion Oncology AS's Debt-to-Asset falls into.



Scandion Oncology AS Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Scandion Oncology AS's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Scandion Oncology AS's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scandion Oncology AS  (OSTO:SCOL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Scandion Oncology AS Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Scandion Oncology AS's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Scandion Oncology AS Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology AS Headlines

No Headlines